Synthesis and Activity against Multidrug Resistance in Chinese Hamster Ovary Cells of New Acridone-4-carboxamides

Journal of Medicinal Chemistry

Volumn 38, Issue 13, 1995, Pages 2418-2426

  Dodic, Nérina ^a   Dumaitre, Bernard ^a   Daugan, Alain ^a   Pianetti, Pascal ^a  

^a ZA de Courtaboeuf ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

9,10 DIHYDRO 5 METHOXY 9 OXO N [4 [2 (1,2,3,4 TETRAHYDRO 6,7 DIMETHOXYISOQUINOL 2 YL)ETHYL]PHENYL] 4 ACRIDINECARBOXAMIDE; ACRIDONE DERIVATIVE; AMIDE; AMIODARONE; BENZYL DERIVATIVE; ELACRIDAR; GLYCOPROTEIN P; PHENETHYLAMINE; PHENYL GROUP; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; CHO CELL; DRUG ACTIVITY; DRUG SYNTHESIS; MULTIDRUG RESISTANCE; NONHUMAN;

ACRIDINES; ANIMAL; CELL LINE; CHO CELLS; CRICETULUS; DRUG RESISTANCE, MULTIPLE; HAMSTERS; MICE; P-GLYCOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029011403     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00013a017     Document Type: Article

References (22)

1. Pastan, I.; Gottesman, M. M. Multidrug resistance in human cancer. N. Engl. J. Med. 1987, 316, 1388-1393.
2. Bradley, G.; Juranka, P. F.; Ling, U. Mechanism of drug resistance. Biochim. Biophys. Acta 1988, 948, 87-128.
3. Endicott, J. A.; Ling, U. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu. Rev. Biochem. 1989, 58, 137-171.
4. Abramson, R.; Bhushan, A.; Dolci, E.; Tritton, T. R. The structure of the multidrug resistance P-glycoprotein and its similarity to other proteins. Annual Reports in medicinal chemistry, Academic Press: New York, 1990; Vol. 25, Chapter 27, pp 253-260.
5. Tsuruo, T.; Lida, H.; Tsukagoshi, S. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytoxicity of vincrinstine and vinblastine by verapamil. Cancer Res. 1981, 41, 1967-1972.
6. Tsuruo, T.; Lida, H.; Tsukagoshi, S. Increased accumulation of vincristine and adriamicin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982, 42, 4730-4733.
7. Kessel, D.; Wilberding, C. Promotion of daunorubicin uptake and toxicity by the calcium antagonist thiapamil and its analogs. Cancer Treat. Rep. 1985, 69, 673-676.
8. Chauffert, B.; Martin, M.; Hamman, M.; Michel, M. F.; Martin, F. Amiodarone-induced enhancement at doxorubicin and 4•. Deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res. 1986, 46, 825-830.
9. Slater, L.; Sweet, P.; Stupecky, M.; Wetzel, M. W.; Gupta, S. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br. J. Cancer. 1986, 77, 1405-1408.
10. Pennock, G. D.; Dalton, W. S.; Roeske, W. R. Systemic toxic effects associated with high dose verapamil infusion and chemotherapy administration. J. Natl. Cancer Inst. 1991, 83, 105-110.
11. Zamora, J. M.; Pearce, H. L.; Beck, W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukaemia cells. Mol. Pharmacol. 1988, 33, 454-462.
12. Ford, J. M.; Prozialeck, W. C.; Hait, N. N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol. 1989, 35, 105-115.
13. Nogae, I.; Kimitoshi, K.; Kikuchi, J. Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labelling of P-glycoprotein. Biochem. Pharmacol. 1989, 38, 519-527.
14. Dhainaut, A.; Rbgnier, G.; Atassi, G.; Pierre, A.; Lonce, S.; Kraus-Berthier, L.; Prost, J. F. New triazine derivatives as potent modulators of multidrug resistance. J. Med. Chem. 1992, 35, 2481-2496.
15. Morgan, T. K.; Wohl, R. A.; Lumma, W. C., Jr.; Chungenan, W.; Davey, D. D.; Gomez, R. P.; Marisca, A. J.; Briggs, M.; Sullivan, M. E.; Wong, S. S. Synthesis and Class III antiarrhytmic activity of (phenylbut-2-enyl) ammonium salts. Effect of conformation on activity. J. Med. Chem. 1986, 29, 1398-1405.
16. Kiefer, E. F. A rapid, convenient preparative procedure for phenethylamines. J. Med. Chem. 1972, 15, 214.
17. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993, 53, 4595-4602.
18. Atwell, G. J.; Cain, B. F.; Baguley, B. C.; Finlay, G. J.; Denny, W. A. Potential antitumor agents. 43. Synthesis and biological activity of dibasic-9-aminoacridine-4-carboxamides, a new class of antitumor agent. J. Med. Chem. 1984, 27, 1481-1485.
19. Palmer, B. D.; Rewcastle, G. W.; Atwell, G. J.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides. J. Med. Chem. 1988, 31, 707-712 and references cited therein.
20. Rewcastle, G. W.; Denny, W. A.; Baguley, B. C. Potential antitumor agents. 51. Synthesis and antitumor activity of substituted phenazine-l-carboxamides. J. Med. Chem. 1987, 30, 843-851.
21. Atwell, G. J.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 57. 2-phenyl-quinoline-8-carboxamides as “minimal” DNA intercalating antitumor agents with in vivo solid tumor activity. J. Med. Chem. 1989, 32, 396-401.
22. Rewcastle, G. W.; Denny, W. A. The synthesis of substituted 9-oxoacridan-4-carboxylic acids, part 2. The use 2-iodoisoph- thalic acid in the Jourdan. Ullmann reaction. Synthesis 1985, 2, 217-220.